FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3130620281> ?p ?o ?g. }

• W3130620281 endingPage "311" @default.
• W3130620281 startingPage "300" @default.
• W3130620281 abstract "Although boron neuron capture therapy (BNCT) has enabled the delivery of stronger radiation dose to glioblastoma multiforme (GBM) cells for precision radiotherapy (RT), patients in need are almost unable to access the treatment due to insufficient operating devices. Therefore, we developed targeted sensitization-enhanced radiotherapy (TSER), a strategy that could achieve precision cell-targeted RT using common linear accelerators. TSER, which involves the combination of GoldenDisk (GD; a spherical radioenhancer), 5-aminolevulinic acid (5-ALA), low-intensity ultrasound (US), and low-dose RT, exhibited synergized radiosensitization effects. Both 5-ALA and hyaluronic-acid-immobilized GD can selectively accumulate in GBM to induce chemical and biological enhancement of radiosensitization, resulting in DNA damage, escalation of reactive oxygen species levels, and cell cycle redistribution, in turn sensitizing GBM cells to radiation under US. TSER showed an enhanced therapeutic effect and survival in the treatment of an orthotropic GBM model with only 20% of the radiation dose compared to that of a 10-Gy RT. The strategy with the potential to inhibit GBM progress and rescue the organ at risk using low-dose RT, thereby improving the quality of life of GBM patients, shedding light on achieving cell-targeted RT using universally available linear accelerators. We invented GoldenDisk (GD), a radioenhancer with hyaluronic-acid (HAc)-coated gold nanoparticle (AuNP)-core/silica shell nanoparticle, to make radiotherapy (RT) safer and smarter. The surface modification of HAc and silica allows GD to target CD44-overexpressed glioblastoma multiforme (GBM) cells and stay structurally stable in cytoplasm throughout the course of RT. By combining GD with low-energy ultrasound and an FDA-approved imaging agent, 5-aminolevulinic acid (5-ALA), GBM cells were sensitized to RT leaving healthy tissues in the vicinity unaffected. The ionized radiation can further be transferred to photoelectronic products with higher cytotoxicity by GD upon collision, achieving higher therapeutic efficacy. With the newly-developed strategy, we are able to achieve low-dose precision RT with the use of only 20% radiation dose." @default.
• W3130620281 created "2021-03-01" @default.
• W3130620281 creator A5003313744 @default.
• W3130620281 creator A5006688634 @default.
• W3130620281 creator A5025899152 @default.
• W3130620281 creator A5039690957 @default.
• W3130620281 creator A5059855908 @default.
• W3130620281 creator A5084297008 @default.
• W3130620281 creator A5088387698 @default.
• W3130620281 creator A5089402019 @default.
• W3130620281 date "2021-04-01" @default.
• W3130620281 modified "2023-10-17" @default.
• W3130620281 title "Tumor cell-targeting radiotherapy in the treatment of glioblastoma multiforme using linear accelerators" @default.
• W3130620281 cites W1975907146 @default.
• W3130620281 cites W1991233540 @default.
• W3130620281 cites W1994709852 @default.
• W3130620281 cites W1998080912 @default.
• W3130620281 cites W2033861133 @default.
• W3130620281 cites W2084186494 @default.
• W3130620281 cites W2096045637 @default.
• W3130620281 cites W2108570354 @default.
• W3130620281 cites W2132834292 @default.
• W3130620281 cites W2153893679 @default.
• W3130620281 cites W2154745425 @default.
• W3130620281 cites W2282233485 @default.
• W3130620281 cites W2341363697 @default.
• W3130620281 cites W2583158155 @default.
• W3130620281 cites W2585659713 @default.
• W3130620281 cites W2589092100 @default.
• W3130620281 cites W2734551289 @default.
• W3130620281 cites W2768044186 @default.
• W3130620281 cites W2783416774 @default.
• W3130620281 cites W2804862738 @default.
• W3130620281 cites W2900529161 @default.
• W3130620281 cites W2904787830 @default.
• W3130620281 cites W2907040479 @default.
• W3130620281 cites W2913317399 @default.
• W3130620281 cites W2924505499 @default.
• W3130620281 cites W2940667300 @default.
• W3130620281 cites W2976542982 @default.
• W3130620281 cites W2977395251 @default.
• W3130620281 cites W2985929952 @default.
• W3130620281 cites W3021719264 @default.
• W3130620281 cites W3023757275 @default.
• W3130620281 cites W3045442856 @default.
• W3130620281 cites W3081805026 @default.
• W3130620281 doi "https://doi.org/10.1016/j.actbio.2021.02.019" @default.
• W3130620281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33609743" @default.
• W3130620281 hasPublicationYear "2021" @default.
• W3130620281 type Work @default.
• W3130620281 sameAs 3130620281 @default.
• W3130620281 citedByCount "9" @default.
• W3130620281 countsByYear W31306202812022 @default.
• W3130620281 countsByYear W31306202812023 @default.
• W3130620281 crossrefType "journal-article" @default.
• W3130620281 hasAuthorship W3130620281A5003313744 @default.
• W3130620281 hasAuthorship W3130620281A5006688634 @default.
• W3130620281 hasAuthorship W3130620281A5025899152 @default.
• W3130620281 hasAuthorship W3130620281A5039690957 @default.
• W3130620281 hasAuthorship W3130620281A5059855908 @default.
• W3130620281 hasAuthorship W3130620281A5084297008 @default.
• W3130620281 hasAuthorship W3130620281A5088387698 @default.
• W3130620281 hasAuthorship W3130620281A5089402019 @default.
• W3130620281 hasConcept C105702510 @default.
• W3130620281 hasConcept C126322002 @default.
• W3130620281 hasConcept C1491633281 @default.
• W3130620281 hasConcept C185592680 @default.
• W3130620281 hasConcept C192562407 @default.
• W3130620281 hasConcept C2776194525 @default.
• W3130620281 hasConcept C2777529286 @default.
• W3130620281 hasConcept C2989005 @default.
• W3130620281 hasConcept C502942594 @default.
• W3130620281 hasConcept C509974204 @default.
• W3130620281 hasConcept C55493867 @default.
• W3130620281 hasConcept C71924100 @default.
• W3130620281 hasConceptScore W3130620281C105702510 @default.
• W3130620281 hasConceptScore W3130620281C126322002 @default.
• W3130620281 hasConceptScore W3130620281C1491633281 @default.
• W3130620281 hasConceptScore W3130620281C185592680 @default.
• W3130620281 hasConceptScore W3130620281C192562407 @default.
• W3130620281 hasConceptScore W3130620281C2776194525 @default.
• W3130620281 hasConceptScore W3130620281C2777529286 @default.
• W3130620281 hasConceptScore W3130620281C2989005 @default.
• W3130620281 hasConceptScore W3130620281C502942594 @default.
• W3130620281 hasConceptScore W3130620281C509974204 @default.
• W3130620281 hasConceptScore W3130620281C55493867 @default.
• W3130620281 hasConceptScore W3130620281C71924100 @default.
• W3130620281 hasFunder F4320322795 @default.
• W3130620281 hasFunder F4320323468 @default.
• W3130620281 hasFunder F4320327358 @default.
• W3130620281 hasLocation W31306202811 @default.
• W3130620281 hasOpenAccess W3130620281 @default.
• W3130620281 hasPrimaryLocation W31306202811 @default.
• W3130620281 hasRelatedWork W1583321654 @default.
• W3130620281 hasRelatedWork W1608751186 @default.
• W3130620281 hasRelatedWork W2240326705 @default.
• W3130620281 hasRelatedWork W2372455565 @default.
• W3130620281 hasRelatedWork W2385269431 @default.

• next